Moderna Valuation
| MRNA Stock | USD 25.55 0.45 1.73% |
At this time, the firm appears to be undervalued. Moderna secures a last-minute Real Value of $30.04 per share. The latest price of the firm is $25.55. Our model forecasts the value of Moderna from analyzing the firm fundamentals such as Return On Equity of -0.29, profit margin of (1.06) %, and Current Valuation of 4.65 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Moderna's valuation include:
Price Book 1.0247 | Enterprise Value | Enterprise Value Ebitda 4.6412 | Price Sales 3.2466 | Forward PE 32.4675 |
Undervalued
Today
Please note that Moderna's price fluctuation is not too volatile at this time. Calculation of the real value of Moderna is based on 3 months time horizon. Increasing Moderna's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Moderna is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moderna Stock. However, Moderna's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.55 | Real 30.04 | Target 46.96 | Hype 25.66 | Naive 24.22 |
The real value of Moderna Stock, also known as its intrinsic value, is the underlying worth of Moderna Company, which is reflected in its stock price. It is based on Moderna's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Moderna's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Moderna helps investors to forecast how Moderna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moderna more accurately as focusing exclusively on Moderna's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Moderna's intrinsic value based on its ongoing forecasts of Moderna's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Moderna's closest peers. If more than one evaluation category is relevant for Moderna we suggest using both methods to arrive at a better estimate.
Moderna Cash |
|
Moderna Valuation Trend
Comparing Moderna's enterprise value against its market capitalization is a good way to estimate the value of Moderna uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Moderna Total Value Analysis
Moderna is now estimated to have valuation of 4.65 B with market capitalization of 10.06 B, debt of 747 M, and cash on hands of 8.35 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Moderna fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.65 B | 10.06 B | 747 M | 8.35 B |
Moderna Investor Information
About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moderna recorded a loss per share of 8.58. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of August 2017. Based on the key measurements obtained from Moderna's financial statements, Moderna may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Moderna Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Moderna has an asset utilization ratio of 22.88 percent. This suggests that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Moderna is more efficient with each dollar of assets it utilizes for everyday operations.Moderna Ownership Allocation
Moderna maintains a total of 386.74 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. On March 28, 2025, Representative Rob Bresnahan of US Congress acquired under $15k worth of Moderna's common stock.Moderna Profitability Analysis
The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.62 B).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Moderna's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Moderna and how it compares across the competition.
About Moderna Valuation
The stock valuation mechanism determines Moderna's current worth on a weekly basis. Our valuation model uses a comparative analysis of Moderna. We calculate exposure to Moderna's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Moderna's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.8 B | 3.3 B | |
| Pretax Profit Margin | (1.11) | (1.17) | |
| Operating Profit Margin | (1.22) | (1.28) | |
| Net Loss | (1.10) | (1.16) | |
| Gross Profit Margin | 0.55 | 0.57 |
Moderna Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 384 M | |
| Quarterly Earnings Growth Y O Y | -0.851 | |
| Forward Price Earnings | 32.4675 |
Moderna Current Valuation Indicators
Valuation refers to the process of determining the present value of Moderna and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Moderna we look at many different elements of the entity such as Moderna's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Moderna, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Moderna's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Moderna's worth.Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |